Clinical Trials

92 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT02523014 2026-05-08

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Phase 2 Recruiting

124 enrolled

CNS

Meningioma

NCT06982521 2026-05-08

ReDiscover-2

Phase 3 Recruiting

540 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT04439123 2026-05-06

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

35 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04493853 2026-05-05

CAPItello-281

Phase 2 Active not recruiting

1,012 enrolled

Genitourinary

Prostatic Neoplasms

NCT03660826 2026-05-04

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

288 enrolled 21 charts

Sarcoma

Carcinosarcoma, Carcinoma, Endometrioid

NCT03616587 2026-04-30

SERENA-1

Phase 1 Active not recruiting

396 enrolled

Breast Neoplasms

NCT04305496 2026-04-30

CAPItello-291

818 enrolled 19 charts 1 FDA

Phase 1/2 Active not recruiting

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Completed

423 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03742102 2026-04-24

BEGONIA

243 enrolled 13 charts

DermatologicGynecologicHead & NeckSarcoma

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05039801 2026-04-15

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1 Recruiting

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT07241065 2026-04-15

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

Phase 1 Recruiting

42 enrolled

Healthy Participants

NCT06764186 2026-04-08

CAPItana

101 enrolled

Breast Neoplasms

NCT05593497 2026-03-27

SNARE

Phase 2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT06635447 2026-03-27

CAPItrue

258 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms, Disease Progression

NCT07486648 2026-03-24

Precision

53 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07294677 2026-03-04

CAVALRY

LymphoidOther hematologic neoplasm

104 enrolled

Leukemia, Lymphoma

NCT07088913 2026-03-03

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

Phase 1 Completed

20 enrolled

Healthy Participants

NCT07281833 2026-02-27

CAPIcorn

Phase 3 Recruiting

250 enrolled

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07426822 2026-02-24

SAFE-CAP

108 enrolled

Diarrhea, Exanthema

NCT02813135 2026-01-16

ESMART

Phase 2 Active not recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

435 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

159 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

923 enrolled

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04556773 2025-12-17

DB-08

138 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01992952 2025-11-26

FAKTION

149 enrolled